Armata’s AP-SA02 shows promise for SAB

US clinical stage biotech Armata Pharmaceuticals’ (NYSE: ARMP) investigational phage therapy, AP-SA02, demonstrated earlier resolution in patients with Staphylococcus aureus bacteremia (SAB) in a Phase IIa trial, reinforcing the growing clinical promise of bacteriophage-based treatments.

The findings highlight the therapy’s potential to address antibiotic resistance and provide a new treatment option for patients with serious bloodstream infections, says pharma analytics company GlobalData.

Stephanie Kurdach, infectious disease analyst at GlobalData, commented: “Bacteriophages, or phages, are viruses that can selectively target and kill bacteria. Phages are particularly advantageous anti-infectives because they can target antibiotic-resistant bacteria, such as S. aureus. The World Health Organization (WHO) has categorized methicillin-resistant S. aureus (MRSA) as a high-priority pathogen in the 2024 WHO Bacterial Priority Pathogen1s List.”